Exelixis in-licences onco molecule developed by Dr Reddy’s arm, Health News, ET HealthWorld

Hyderabad: Pharma major Dr Reddy’s Laboratories on Tuesday informed the bourses that US-based Exelixis Inc has in-licenced Aurigene Discovery Technologies Ltd’s novel CDK7 inhibitor XL102 (formerly AUR102) and filed an investigational new drug application with the US Food & Drug Administration (USFDA) for Phase I clinical trials of the molecule for advanced solid tumours.

Aurigene, which is a development stage biotech company engaged in discovery and clinical development of novel and best-in-class therapies to treat cancer and inflammatory diseases, is a wholly owned subsidiary of Dr Reddy’s Laboratories. The Phase I clinical trials of XL102, which will evaluate it alone or in combination therapy for the treatment of inoperable locally advanced or metastatic solid tumors, are expected to begin in the first quarter of 2021.

Follow and connect with us on , Facebook, Linkedin

Source link